Levetiracetam Tillomed

Levetiracetam, the active ingredient in Levetiracetam Tillomed, is an anticonvulsant presented as an intravenous solution for IV use. It is employed to treat partial and generalized seizure disorders in patients requiring parenteral therapy. It is indicated for patients with refractory epilepsy and is available for intravenous administration in acute care settings.

GNH USA supplies Levetiracetam Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Levetiracetam is an anticonvulsant that acts on neuronal excitability to control seizure activity. - Partial seizures: reduces frequency and severity of focal onset seizures. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes in patients with generalized epilepsy. - Myoclonic seizures: decreases occurrence of sudden muscle jerks associated with myoclonic epilepsy. - Adjunct therapy: used as add‑on treatment when seizures are not controlled by other antiepileptics.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to severe. Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: persistent tiredness or lack of energy. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate cranial pain. - Irritability: mood changes including agitation. - Nausea: upset stomach or urge to vomit. Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: serious skin disorder with blistering. - Blood dyscrasias: neutropenia or thrombocytopenia. - Suicidal thoughts: emergence of depressive ideation. - Severe depression: marked mood disturbances. - Rash with mucosal involvement: potential toxic epidermal necrolysis.

When prescribing Levetiracetam, clinicians should consider several safety precautions to minimise risk. - Renal impairment: adjust dose based on creatinine clearance. - Hepatic impairment: monitor liver function tests. - Pregnancy: potential unknown risks; use only if benefit outweighs risk. - Concomitant CNS depressants: may enhance sedation. - Mood changes: observe for depression or suicidal ideation. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Levetiracetam can interact with other medicines, influencing its plasma levels or enhancing side‑effects. Major Interactions (Avoid): - Carbamazepine: reduces levetiracetam concentrations. - Phenobarbital: decreases levetiracetam exposure. - Phenytoin: may lower levetiracetam levels. - Rifampin: induces metabolism, lowering efficacy. - Enzyme‑inducing antiepileptics: overall decrease drug exposure. Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression. - Other antiepileptics: may require dose adjustments. - Oral contraceptives: possible reduced hormonal efficacy. - Sedatives or hypnotics: increased drowsiness. - Antidepressants: monitor for mood changes.